1.Relationship between Changes of Treg/Th17 Ratio and Curative Effect in Patients with HBeAg?positive Chronic Hepatitis B after Receiving Entecavir
Chengwei LI ; Dan LU ; Yan NA ; Yan LI ; Benxin WANG ; Xianzhi LOU
Journal of China Medical University 2017;46(1):33-35,40
Objective To investigate whether there are correlation among changes of Treg/Th17 ratio with virological response and serological re?sponse in patients with hepatitis B e antigen(HBeAg)?positive chronic hepatitis B(CHB)after receiving entecavir. Methods 27 patients with HBeAg?positive CHB were enrolled for the study. Peripheral blood Treg cell frequency and Th17 cell frequency,HBV DNA,alanine aminotransfer?ase levels,hepatitis B virus marker were detected before and after entecavir treatment at 4,12,24,36,and 48 weeks. Peripheral blood Treg cell frequency and Th17 cell frequency of 20 healthy volunteers were detected as well. Results Treg/Th17 ratio of patients decreased from 4 week and reached the lowest point at 12 weeks. Treg/Th17 ratio(12 weeks)of the patients who got the early virological response and HBeAg disappeared was lower than others,and the difference was statistical significant. Conclusion Treg/Th17 ratio changes in HBeAg?positive CHB patients receiv?ing entecavir antiviral treatment. Treg/Th17 ratio(12 weeks)showed significant correlation with early virological response and HBeAg disappear?ance. The changes of Treg/Th17 ratio may provide a reference of curative effect.
2.Effects of angiotensin II receptor blocker usage on viral load, antibody dynamics, and transcriptional characteristics among COVID-19 patients with hypertension.
Baihuan FENG ; Dan ZHANG ; Qi WANG ; Fei YU ; Qianda ZOU ; Guoliang XIE ; Ruonan WANG ; Xianzhi YANG ; Weizhen CHEN ; Bin LOU ; Shufa ZHENG ; Yu CHEN
Journal of Zhejiang University. Science. B 2021;22(4):330-340
Epidemiological evidence suggests that patients with hypertension infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are at increased risk of acute lung injury. However, it is still not clear whether this increased risk is related to the usage of renin-angiotensin system (RAS) blockers. We collected medical records of coronavirus disease 2019 (COVID-19) patients from the First Affiliated Hospital, Zhejiang University School of Medicine (Hangzhou, China), and evaluated the potential impact of an angiotensin II receptor blocker (ARB) on the clinical outcomes of COVID-19 patients with hypertension. A total of 30 hypertensive COVID-19 patients were enrolled, of which 17 were classified as non-ARB group and the remaining 13 as ARB group based on the antihypertensive therapies they received. Compared with the non-ARB group, patients in the ARB group had a lower proportion of severe cases and intensive care unit (ICU) admission as well as shortened length of hospital stay, and manifested favorable results in most of the laboratory testing. Viral loads in the ARB group were lower than those in the non-ARB group throughout the disease course. No significant difference in the time of seroconversion or antibody levels was observed between the two groups. The median levels of soluble angiotensin-converting enzyme 2 (sACE2) in serum and urine samples were similar in both groups, and there were no significant correlations between serum sACE2 and biomarkers of disease severity. Transcriptional analysis showed 125 differentially expressed genes which mainly were enriched in oxygen transport, bicarbonate transport, and blood coagulation. Our results suggest that ARB usage is not associated with aggravation of COVID-19. These findings support the maintenance of ARB treatment in hypertensive patients diagnosed with COVID-19.
Aged
;
Aged, 80 and over
;
Angiotensin Receptor Antagonists/therapeutic use*
;
Angiotensin-Converting Enzyme 2/blood*
;
Antibodies, Viral/blood*
;
Antihypertensive Agents/therapeutic use*
;
Biomarkers
;
COVID-19/complications*
;
China
;
Female
;
Humans
;
Hypertension/drug therapy*
;
Intensive Care Units
;
Length of Stay
;
Male
;
Middle Aged
;
Retrospective Studies
;
Transcriptome
;
Viral Load